Candidates: Vaccines targeting SARS-CoV-2

Types: Vaccines based on the company’s virus-like particle (VLP) based platform technologies METAVAX® and SplitCore.

Status: ARTES said April 27 it will develop SARS-CoV-2 vaccine candidates designed to present domains of the spike protein of SARS-CoV-2—with or without an antigen derived from the virus’ nucleocapsid protein—on the surface of enveloped virus-like particle nanostructures (eVLPs) via METAVAX, and on capsid virus-like particles (cVLPs) via SplitCore. METAVAX uses eVLPs based on the duck Hepatitis B small surface antigen, while SplitCore applies cVLPs as antigen presentation vehicles without involvement of host lipid membrane structures.

In September 2019, ARTES and Australian Burnett Institute published data in PLoS ONE on the efficient production of malaria vaccine candidates using eVLPs produced with METAVAX-presenting malaria transmission-stage antigens, which were capable of inducing transmission-blocking antibodies. For SplitCore, borrelia antigen presenting cVLP were developed by a research team of the University of Freiburg and resulted in the induction of neutralizing antibodies against Lyme disease, ARTES said.

COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types: